These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 28949293)
41. Towards a vaccine against Plasmodium vivax malaria. Beeson JG; Crabb BS PLoS Med; 2007 Dec; 4(12):e350. PubMed ID: 18092888 [TBL] [Abstract][Full Text] [Related]
42. Immunoreactivity of Sera From Low to Moderate Malaria-Endemic Areas Against Arévalo-Herrera M; Miura K; Cespedes N; Echeverry C; Solano E; Castellanos A; Ramirez JS; Miranda A; Kajava AV; Long C; Corradin G; Herrera S Front Immunol; 2021; 12():634738. PubMed ID: 34248932 [TBL] [Abstract][Full Text] [Related]
43. The association of Duffy binding protein region II polymorphisms and its antigenicity in Plasmodium vivax isolates from Thailand. Chootong P; McHenry AM; Ntumngia FB; Sattabongkot J; Adams JH Parasitol Int; 2014 Dec; 63(6):858-64. PubMed ID: 25108177 [TBL] [Abstract][Full Text] [Related]
44. Humoral immune responses to a recombinant Plasmodium vivax tryptophan-rich antigen among Plasmodium vivax-infected patients and its localization in the parasite. Siddiqui AA; Khan F; Sharma YD Appl Biochem Biotechnol; 2015 Feb; 175(4):2166-77. PubMed ID: 25467946 [TBL] [Abstract][Full Text] [Related]
45. The acquisition of long-lived memory B cell responses to merozoite surface protein-8 in individuals with Plasmodium vivax infection. Kochayoo P; Kittisenachai N; Changrob S; Wangriatisak K; Muh F; Chootong P; Han ET Malar J; 2019 May; 18(1):188. PubMed ID: 31151441 [TBL] [Abstract][Full Text] [Related]
46. Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein. Grimberg BT; Udomsangpetch R; Xainli J; McHenry A; Panichakul T; Sattabongkot J; Cui L; Bockarie M; Chitnis C; Adams J; Zimmerman PA; King CL PLoS Med; 2007 Dec; 4(12):e337. PubMed ID: 18092885 [TBL] [Abstract][Full Text] [Related]
47. Vaccination with recombinant Plasmodium vivax MSP-10 formulated in different adjuvants induces strong immunogenicity but no protection. Giraldo MA; Arevalo-Pinzon G; Rojas-Caraballo J; Mongui A; Rodriguez R; Patarroyo MA Vaccine; 2009 Dec; 28(1):7-13. PubMed ID: 19782110 [TBL] [Abstract][Full Text] [Related]
48. Evaluation of the genetic diversity of domain II of Plasmodium vivax Apical Membrane Antigen 1 (PvAMA-1) and the ensuing strain-specific immune responses in patients from Sri Lanka. Dias S; Somarathna M; Manamperi A; Escalante AA; Gunasekera AM; Udagama PV Vaccine; 2011 Oct; 29(43):7491-504. PubMed ID: 21784116 [TBL] [Abstract][Full Text] [Related]
50. The antigenicity of a Plasmodium vivax reticulocyte binding protein-1 (PvRBP1) recombinant fragment in humans and its immunogenicity and protection studies in Aotus monkeys. Rojas Caraballo J; Delgado G; Rodriguez R; Patarroyo MA Vaccine; 2007 May; 25(18):3713-21. PubMed ID: 17240494 [TBL] [Abstract][Full Text] [Related]
54. Antibody levels to multiple malaria vaccine candidate antigens in relation to clinical malaria episodes in children in the Kasena-Nankana district of Northern Ghana. Dodoo D; Atuguba F; Bosomprah S; Ansah NA; Ansah P; Lamptey H; Egyir B; Oduro AR; Gyan B; Hodgson A; Koram KA Malar J; 2011 May; 10():108. PubMed ID: 21529376 [TBL] [Abstract][Full Text] [Related]
55. Identification and Immunological Characterization of the Ligand Domain of Plasmodium vivax Reticulocyte Binding Protein 1a. Ntumngia FB; Thomson-Luque R; Galusic S; Frato G; Frischmann S; Peabody DS; Chackerian B; Ferreira MU; King CL; Adams JH J Infect Dis; 2018 Aug; 218(7):1110-1118. PubMed ID: 29741629 [TBL] [Abstract][Full Text] [Related]
56. Efficacy of a Plasmodium vivax malaria vaccine using ChAd63 and modified vaccinia Ankara expressing thrombospondin-related anonymous protein as assessed with transgenic Plasmodium berghei parasites. Bauza K; Malinauskas T; Pfander C; Anar B; Jones EY; Billker O; Hill AV; Reyes-Sandoval A Infect Immun; 2014 Mar; 82(3):1277-86. PubMed ID: 24379295 [TBL] [Abstract][Full Text] [Related]
57. Malaria transmission and individual variability of the naturally acquired IgG antibody against the Plasmodium vivax blood-stage antigen in an endemic area in Brazil. Costa EMF; Amador ECC; Silva ES; Alvarenga CO; Pereira PE; Póvoa MM; Cunha MG Acta Trop; 2020 Sep; 209():105537. PubMed ID: 32454033 [TBL] [Abstract][Full Text] [Related]
58. Naturally-acquired humoral immune responses against the N- and C-termini of the Plasmodium vivax MSP1 protein in endemic regions of Brazil and Papua New Guinea using a multiplex assay. Fernandez-Becerra C; Sanz S; Brucet M; Stanisic DI; Alves FP; Camargo EP; Alonso PL; Mueller I; del Portillo HA Malar J; 2010 Jan; 9():29. PubMed ID: 20092651 [TBL] [Abstract][Full Text] [Related]
59. B cell epitope mapping and characterization of naturally acquired antibodies to the Plasmodium vivax merozoite surface protein-3α (PvMSP-3α) in malaria exposed individuals from Brazilian Amazon. Lima-Junior JC; Jiang J; Rodrigues-da-Silva RN; Banic DM; Tran TM; Ribeiro RY; Meyer VS; De-Simone SG; Santos F; Moreno A; Barnwell JW; Galinski MR; Oliveira-Ferreira J Vaccine; 2011 Feb; 29(9):1801-11. PubMed ID: 21215342 [TBL] [Abstract][Full Text] [Related]
60. Immunogenicity and protective efficacy of recombinant vaccine based on the receptor-binding domain of the Plasmodium vivax Duffy binding protein in Aotus monkeys. Arévalo-Herrera M; Castellanos A; Yazdani SS; Shakri AR; Chitnis CE; Dominik R; Herrera S Am J Trop Med Hyg; 2005 Nov; 73(5 Suppl):25-31. PubMed ID: 16291763 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]